These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 29387948)

  • 1. Expression of Hippo signaling pathway and Aurora kinase genes in chronic myeloid leukemia.
    Marsola APZC; Simões BP; Palma LC; Berzoti-Coelho MG; Burin SM; de Castro FA
    Med Oncol; 2018 Jan; 35(3):26. PubMed ID: 29387948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors.
    Mancini M; De Santis S; Monaldi C; Bavaro L; Martelli M; Castagnetti F; Gugliotta G; Rosti G; Santucci MA; Martinelli G; Cavo M; Soverini S
    J Exp Clin Cancer Res; 2019 May; 38(1):216. PubMed ID: 31122263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
    Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
    Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
    Ferri C; Bianchini M; Bengió R; Larripa I
    Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.
    Gleixner KV; Ferenc V; Peter B; Gruze A; Meyer RA; Hadzijusufovic E; Cerny-Reiterer S; Mayerhofer M; Pickl WF; Sillaber C; Valent P
    Cancer Res; 2010 Feb; 70(4):1513-23. PubMed ID: 20145140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of an aurora kinase inhibitor and the ABL tyrosine kinase inhibitor asciminib against ABL inhibitor-resistant CML cells.
    Okabe S; Moriyama M; Gotoh A
    Med Oncol; 2024 May; 41(6):142. PubMed ID: 38714583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stem Cell Responsiveness to Imatinib in Chronic Myeloid Leukemia.
    Lahlil R; Aries A; Scrofani M; Zanetti C; Hennequin D; Drénou B
    Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38068992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversine triggers mitotic catastrophe and apoptosis in K562 cells.
    Rodrigues Alves AP; Machado-Neto JA; Scheucher PS; Paiva HH; Simões BP; Rego EM; Traina F
    Leuk Res; 2016 Sep; 48():26-31. PubMed ID: 27447890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
    Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D
    Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of Tpl2 is linked to imatinib resistance and activation of MEK-ERK and NF-κB pathways in a model of chronic myeloid leukemia.
    Chorzalska A; Ahsan N; Rao RSP; Roder K; Yu X; Morgan J; Tepper A; Hines S; Zhang P; Treaba DO; Zhao TC; Olszewski AJ; Reagan JL; Liang O; Gruppuso PA; Dubielecka PM
    Mol Oncol; 2018 May; 12(5):630-647. PubMed ID: 29485707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of anti-apoptotic pathways activated by BCR/ABL in the resistance of chronic myeloid leukemia cells to tyrosine kinase inhibitors.
    Danisz K; Blasiak J
    Acta Biochim Pol; 2013; 60(4):503-14. PubMed ID: 24273759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.
    Ali MA
    Mol Diagn Ther; 2016 Aug; 20(4):315-33. PubMed ID: 27220498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Exposure to Imatinib Mesylate Downregulates Hippo Pathway and Activates YAP in a Model of Chronic Myelogenous Leukemia.
    Chorzalska A; Kim JF; Roder K; Tepper A; Ahsan N; Rao RSP; Olszewski AJ; Yu X; Terentyev D; Morgan J; Treaba DO; Zhao TC; Liang O; Gruppuso PA; Dubielecka PM
    Stem Cells Dev; 2017 May; 26(9):656-677. PubMed ID: 28103766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AT9283 exhibits antiproliferative effect on tyrosine kinase inhibitor‑sensitive and ‑resistant chronic myeloid leukemia cells by inhibition of Aurora A and Aurora B.
    Takeda T; Tsubaki M; Genno S; Nemoto C; Onishi Y; Yamamoto Y; Imano M; Satou T; Nishida S
    Oncol Rep; 2020 Nov; 44(5):2211-2218. PubMed ID: 33000229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HMGCLL1 is a predictive biomarker for deep molecular response to imatinib therapy in chronic myeloid leukemia.
    Park JH; Woo YM; Youm EM; Hamad N; Won HH; Naka K; Park EJ; Park JH; Kim HJ; Kim SH; Kim HJ; Ahn JS; Sohn SK; Moon JH; Jung CW; Park S; Lipton JH; Kimura S; Kim JW; Kim DDH
    Leukemia; 2019 Jun; 33(6):1439-1450. PubMed ID: 30555164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experimental and integrative analyses identify an ETS1 network downstream of BCR-ABL in chronic myeloid leukemia (CML).
    Desterke C; Voldoire M; Bonnet ML; Sorel N; Pagliaro S; Rahban H; Bennaceur-Griscelli A; Cayssials E; Chomel JC; Turhan AG
    Exp Hematol; 2018 Aug; 64():71-83.e8. PubMed ID: 29733872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of LATS kinases reduces tumorigenicity and increases the sensitivity of human chronic myelogenous leukemia cells to imatinib.
    Klaihmon P; Lorthongpanich C; Kheolamai P; Saisaard W; Issaragrisil S
    Sci Rep; 2024 Feb; 14(1):3993. PubMed ID: 38368446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PKC-β/Alox5 axis activation promotes Bcr-Abl-independent TKI-resistance in chronic myeloid leukemia.
    Ma D; Liu P; Wang P; Zhou Z; Fang Q; Wang J
    J Cell Physiol; 2021 Sep; 236(9):6312-6327. PubMed ID: 33561320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting FLT3-TAZ signaling to suppress drug resistance in blast phase chronic myeloid leukemia.
    Shin JE; Kim SH; Kong M; Kim HR; Yoon S; Kee KM; Kim JA; Kim DH; Park SY; Park JH; Kim H; No KT; Lee HW; Gee HY; Hong S; Guan KL; Roe JS; Lee H; Kim DW; Park HW
    Mol Cancer; 2023 Nov; 22(1):177. PubMed ID: 37932786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of the ETS transcription factor GABPα is positively correlated to the BCR-ABL1/ABL1 ratio in CML patients and affects imatinib sensitivity in vitro.
    Manukjan G; Ripperger T; Santer L; von Neuhoff N; Ganser A; Schambach A; Schlegelberger B; Steinemann D
    Exp Hematol; 2015 Oct; 43(10):880-90. PubMed ID: 26072332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.